SiroSkin试验方案:局部西罗莫司用于实体器官移植受者面部鳞状细胞癌化学预防的随机双盲安慰剂对照试验
SiroSkin是一项多中心III期、参与者和临床评估者盲法、安慰剂对照随机试验,计划入组至少146例实体器官移植受者,1:1随机接受1%局部西罗莫司或安慰剂面部规律涂抹24周,总参与24个月(治疗24周加随访18个月),比较治疗24周及开始治疗后12、24个月时角质形成细胞癌数量,分析按方案和意向性治疗进行。
要点
- SiroSkin为多中心III期随机双盲安慰剂对照试验,评估1%局部西罗莫司对实体器官移植受者面部皮肤癌的化学预防作用。
- 至少146例受者按1:1随机,面部规律涂抹1%局部西罗莫司或安慰剂24周,总参与24个月(治疗24周加随访18个月)。
- 主要比较治疗24周及开始治疗后12、24个月时角质形成细胞癌数量,分析按方案和意向性治疗进行。
核心结论
- 该试验结果将为实体器官移植受者皮肤癌的管理策略提供依据,并为成本效果提供证据。
研究设计与样本
- 多中心III期、参与者和临床评估者盲法、安慰剂对照随机试验,计划入组至少146例实体器官移植受者,按1:1随机接受1%局部西罗莫司或安慰剂面部规律涂抹24周。
- 总参与24个月,包括治疗24周和随访18个月,分析按方案和意向性治疗进行。
主要发现
- 近期一项12周II期试验提示局部西罗莫司在无主要副作用的情况下可安全有效地减少皮肤癌早期征象。
- 局部西罗莫司已在动物模型中证明可有效减少皮肤癌负担,其安全性已在结节性硬化症儿童中长期确立。
关键数值与推荐
- 主要结局为治疗24周时角质形成细胞癌数量与安慰剂比较,并在开始治疗后12个月和24个月时评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Keratinocyte carcinomas such as basal cell carcinomas and squamous cell carcinomas are a major burden affecting morbidity and mortality in solid organ transplant recipients (SOTRs). Best treatment includes frequent skin checks for early detection and surgery for high incidence of skin cancers. Sirolimus is an immunosuppressive drug which may reduce the burden of skin cancer but may be poorly tolerated when given orally. Topical sirolimus has been proven effective at reducing the burden of skin cancers in animal models, and its safety has long been established in children with tuberous sclerosis. A recent 12-week phase II trial of topical sirolimus suggested it was safe and effective at reducing the early signs of skin cancer in the absence of major side effects. The aim of the SiroSkin trial is to determine whether topical sirolimus can fill a major gap in current therapies by reducing the onset and number of new skin cancers thus reducing burden of disease and cost-effectiveness. METHODS: Protocol for a multi-centred phase III, participant- and clinician assessor-blinded, placebo-controlled randomised trial in SOTRs. A minimum 146 participants randomised 1:1 will be treated with 1% topical sirolimus versus placebo applied to the face on a regular basis for 24 weeks. Participation is 24 months in total-24 weeks of treatment and 18 months of follow-up. Outcomes include the number of keratinocyte carcinomas at 24 weeks of treatment compared to placebo and then at 12 and 24 months after initiation of treatment. Analysis will be as per protocol and intention to treat. DISCUSSION: The results of this trial will inform management strategies for skin cancers in SOTRs and provide evidence for cost-effectiveness. TRIAL REGISTRATION: Clinicaltrials.gov NCT05860881. Registered on June 15, 2023, and on anzctr.org.au (registration number NCT05860881).
引用
- Dousset L, Chambers DC, Webster A, et al. Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients. Trials. 2024. PMID: 39578921. doi:10.1186/s13063-024-08619-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。